Home Companies AstraZeneca

AstraZeneca

Latest

Financing

EY Eyes Comeback for Biopharma M&A

Financing

StockWatch: Shares Double for Targets of 3 Buyout Deals Announced at JPM

Cell Therapy

AstraZeneca Acquires Neogene, Expanding in Cancer Cell Therapy

Immuno-oncology

Cancer I-O Pioneer, Executive Target Immune Disruption with $65M Startup

Oncologics

StockWatch: Sierra Oncology Surges on $1.9B GSK Acquisition

AstraZeneca

Wider Arena: Aristea Pursues Excellence with $123M in Investment

AstraZeneca

From Model to Molecule: NVIDIA Doubles Down on AI Drug Discovery

AstraZeneca

AstraZeneca Eyes EUA for COVID-19 Vaccine after Positive Results

AstraZeneca

76% Efficacy, Reduced Transmission Potential Shown by AstraZeneca/Oxford COVID-19 Vaccine

AstraZeneca

AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets

AstraZeneca

AstraZeneca-Oxford COVID-19 Vaccine Shows Positive Phase II Results

Flu Vaccination

AstraZeneca

U.S. Army Awards $599M in Contracts for AstraZeneca Vaccine, Lilly Antibody...

Coronavirus 2019-nCoV spreading

AstraZeneca

AstraZeneca, J&J Resuming Phase III COVID-19 Vaccine Trials

Senior male is about to receive Covid-19 coronavirus vaccine

AstraZeneca

COVID-19: AstraZeneca, U. of Oxford Resume Phase III Trial; Pfizer, BioNTech...

AstraZeneca

AstraZeneca Pauses Phase III COVID-19 Vaccine Trial, Citing “Potentially Unexplained Illness”

12 3...6 Page 1 of 6